|1.||Jacobson, Kenneth A: 4 articles (05/2012 - 03/2002)|
|2.||Morello, Silvana: 4 articles (01/2012 - 02/2008)|
|3.||Pinto, Aldo: 4 articles (01/2012 - 02/2008)|
|4.||Shainberg, Asher: 4 articles (01/2010 - 04/2004)|
|5.||Costa, Vera M: 3 articles (10/2014 - 10/2013)|
|6.||Fresco, Paula: 3 articles (10/2014 - 10/2013)|
|7.||Diniz, Carmen: 3 articles (10/2014 - 10/2013)|
|8.||Soares, Ana S: 3 articles (10/2014 - 10/2013)|
|9.||Borea, Pier Andrea: 3 articles (01/2013 - 06/2007)|
|10.||Varani, Katia: 3 articles (01/2013 - 06/2007)|
01/01/2012 - "Adoptive transfer of Cl-IB-MECA-treated CD8+ T cells or a single administration of Cl-IB-MECA (20 ng/mouse) inhibited tumor growth compared with the control group and significantly improved mouse survival. "
12/01/2012 - "2-Chloro-N(6)-(3-iodobenzyl) adenosine-5'-N-methylcarboxamide (Cl-IB-MECA), an agonist of A3AR, has been reported to induce cell death in various cancer cells. "
01/01/2012 - "Indeed, neutralization of TNF-α by a specific monoclonal Ab significantly blocked the anti-tumor activity of Cl-IB-MECA-treated T cells. "
01/01/2012 - "In mice, Cl-IB-MECA administration enhances the anti-tumor T cell-mediated response. "
04/01/2011 - "In addition, we also found that the number of mature and active conventional dendritic cells at the tumor site was increased after Cl-IB-MECA administration. "
06/01/2007 - "CCPA in both modes of treatment and Cl-IB-MECA, especially in the injected mode, were beneficial in protecting the normal and hypertrophied perfused isolated rat heart subjected to normothermic cardioplegic ischemia. "
04/01/2004 - "CCPA in both modes of treatment and Cl-IB-MECA in the injected mode were beneficial in protecting the perfused isolated rat heart, subjected to normothermic cardioplegic ischemia. "
05/01/2013 - "A selective A3R agonist, Cl-IB-MECA, was administered (100 μg/kg intravenously) 5 minutes prior to ischemia. "
04/01/2004 - "Two different modes of preconditioning were studied: isolated rat hearts were perfused with A(1) receptor agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA) or A(3) 2-chloro-N(6)-(3-iodobenzyl) adenosine-5'-N-methyluronamide (Cl-IB-MECA) (1 nM), followed by cardioplegic ischemia and reperfusion (30 min each) (perfusion mode), or CCPA or Cl-IB-MECA (100 micro g/kg) were injected intravenously 24 h before the experiment (injection mode). "
12/01/2006 - "Cl-IB-MECA did not reduce myocardial infarct size in A(3)KO mice in vivo and did not protect isolated perfused hearts obtained from A(3)KO mice from injury induced by global ischemia and reperfusion. "
05/01/2013 - "The Cl-IB-MECA had no effects in A3R-/- mice; Cl-IB-MECA significantly decreased activation of wild-type, but not A3R-/-, neutrophils after acute hypoxia and reoxygenation and inhibited chemotaxis of wild-type neutrophils. "
12/01/2006 - "In cortical culture, Cl-IB-MECA pretreatment antagonized the hypoxia-mediated decrease in cell viability. "
06/01/2005 - "In cells with elevated intracellular Ca(2+) concentration after hypoxia and treatment with NaN(3) or after application of high doses of NaN(3), Cl-IB-MECA immediately decreased the elevated intracellular Ca(2+) concentration toward the diastolic control level. "
06/01/2005 - "Cl-IB-MECA delayed the dissipation in the mitochondrial membrane potential during hypoxia in cells impaired in the mitochondrial respiratory chain. "
12/01/2010 - "Conclusions Activation of A(1)R or A(3)R by CCPA or Cl-IB-MECA, respectively, protects cardiomyocytes from hypoxia via phosphorylation of p38 MAPK, which is located downstream from the mitochondrial K(ATP) channel opening. "
|4.||Left Ventricular Dysfunction
01/01/2013 - "In vivo Cl-IB-MECA administration, started on day 1 after tumour cell injection, produced a significant reduction in tumour growth and cancer pain. "
01/01/2013 - "The effect of chronic treatment with an A(3)AR agonist, 2-chloro-N(6)-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (Cl-IB-MECA) in comparison with cisplatin, was evaluated on rat tumour growth and bone cancer pain. "
|1.||Adenosine Triphosphate (ATP)
|2.||Caspase 1 (ICE Protease)
|3.||Propidium (Propidium Iodide)
|4.||L-Lactate Dehydrogenase (Lactate Dehydrogenase)
|9.||Purinergic P1 Receptors (Adenosine Receptor)
|10.||N(6)- (3- iodobenzyl)- 5'- N- methylcarboxamidoadenosine